117 related articles for article (PubMed ID: 37991388)
1. A multiomic investigation of lung adenocarcinoma molecular subtypes.
Liang KH; Luo YH; Wang ML; Chiou SH; Chen YM; Hsu HS
J Chin Med Assoc; 2024 Jan; 87(1):33-39. PubMed ID: 37991388
[TBL] [Abstract][Full Text] [Related]
2. Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients.
Ding Y; Zhang L; Guo L; Wu C; Zhou J; Zhou Y; Ma J; Li X; Ji P; Wang M; Zhu W; Shi C; Li S; Wu W; Zhu W; Xiao D; Fu C; He Q; Sun R; Mao X; Lizaso A; Li B; Han-Zhang H; Zhang Z
Thorac Cancer; 2020 Jan; 11(1):103-112. PubMed ID: 31692283
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.
Rothschild SI; Gautschi O; Batliner J; Gugger M; Fey MF; Tschan MP
Lung Cancer; 2017 May; 107():73-83. PubMed ID: 27372519
[TBL] [Abstract][Full Text] [Related]
4. High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study.
Talvitie EM; Vilhonen H; Kurki S; Karlsson A; Orte K; Almangush A; Mohamed H; Liljeroos L; Singh Y; Leivo I; Laitinen T; Kallajoki M; Taimen P
Neoplasia; 2020 Sep; 22(9):333-342. PubMed ID: 32585428
[TBL] [Abstract][Full Text] [Related]
5. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
6. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
7. Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma.
Zhao Y; Gao Y; Xu X; Zhou J; Wang H
BMC Cancer; 2021 Mar; 21(1):257. PubMed ID: 33750346
[TBL] [Abstract][Full Text] [Related]
8. A pilot characterization of human lung NSCLC by protein pathway activation mapping.
Zupa A; Improta G; Silvestri A; Pin E; Deng J; Aieta M; Musto P; Nitti D; Mammano E; Liotta L; Belluco C; Wulfkuhle J; Petricoin E
J Thorac Oncol; 2012 Dec; 7(12):1755-1766. PubMed ID: 23154546
[TBL] [Abstract][Full Text] [Related]
9. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.
Cserepes M; Ostoros G; Lohinai Z; Raso E; Barbai T; Timar J; Rozsas A; Moldvay J; Kovalszky I; Fabian K; Gyulai M; Ghanim B; Laszlo V; Klikovits T; Hoda MA; Grusch M; Berger W; Klepetko W; Hegedus B; Dome B
Eur J Cancer; 2014 Jul; 50(10):1819-1828. PubMed ID: 24768329
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.
Kitagawa S; Zenke Y; Taki T; Aokage K; Sakai T; Shibata Y; Izumi H; Nosaki K; Umemura S; Matsumoto S; Yoh K; Sakamoto N; Sakashita S; Kojima M; Tsuboi M; Goto K; Ishii G
Lung Cancer; 2024 Feb; 188():107453. PubMed ID: 38160515
[TBL] [Abstract][Full Text] [Related]
11. Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors.
Jang HJ; Lee HS; Ramos D; Park IK; Kang CH; Burt BM; Kim YT
J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1598-1610.e3. PubMed ID: 31879171
[TBL] [Abstract][Full Text] [Related]
12. Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma.
Tian Y; Zhao J; Ren P; Wang B; Zhao C; Shi C; Wei B; Ma J; Guo Y
PLoS One; 2018; 13(11):e0201682. PubMed ID: 30383772
[TBL] [Abstract][Full Text] [Related]
13. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
14. Molecular subtypes based on DNA methylation predict prognosis in lung squamous cell carcinoma.
Li XS; Nie KC; Zheng ZH; Zhou RS; Huang YS; Ye ZJ; He F; Tang Y
BMC Cancer; 2021 Jan; 21(1):96. PubMed ID: 33485313
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations.
Zheng D; Wang R; Zhang Y; Pan Y; Cheng X; Cheng C; Zheng S; Li H; Gong R; Li Y; Shen X; Sun Y; Chen H
J Cancer Res Clin Oncol; 2016 Apr; 142(4):833-43. PubMed ID: 26646246
[TBL] [Abstract][Full Text] [Related]
16. Identification of 5-Gene Signature Improves Lung Adenocarcinoma Prognostic Stratification Based on Differential Expression Invasion Genes of Molecular Subtypes.
Zheng Z; Deng W; Yang J
Biomed Res Int; 2020; 2020():8832739. PubMed ID: 33490259
[TBL] [Abstract][Full Text] [Related]
17. Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma.
Wang Q; Tang Z; Li C; Li X; Su C
Front Immunol; 2023; 14():1297588. PubMed ID: 37954616
[TBL] [Abstract][Full Text] [Related]
18. Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma.
Liu W; Wang H; Zhao Q; Tao C; Qu W; Hou Y; Huang R; Sun Z; Zhu G; Jiang X; Fang Y; Gao J; Wu X; Yang Z; Ping R; Chen J; Yang R; Chu T; Zhou J; Fan J; Tang Z; Yang D; Shi Y
Cancer Commun (Lond); 2024 Feb; 44(2):226-250. PubMed ID: 38143235
[TBL] [Abstract][Full Text] [Related]
19. Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma.
Liu K; Guo J; Liu K; Fan P; Zeng Y; Xu C; Zhong J; Li Q; Zhou Y
EBioMedicine; 2018 Oct; 36():196-208. PubMed ID: 30268834
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.
Price KA; Azzoli CG; Krug LM; Pietanza MC; Rizvi NA; Pao W; Kris MG; Riely GJ; Heelan RT; Arcila ME; Miller VA
J Thorac Oncol; 2010 Oct; 5(10):1623-9. PubMed ID: 20871262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
